WPC 2026 Update: The Current State of the Science - Is Parkinson’s Genetic?

What scientists have learned about Parkinson's genes, why genetics matters even if you don't have a mutation, and how targeted therapies may help shape the future of treatment.

For many years, when patients asked whether Parkinson's disease was genetic, the answer was often simple:

"Most Parkinson's disease is not inherited."

While that statement isn't entirely wrong, it is becoming increasingly incomplete.

One of the strongest themes I heard repeatedly at the World Parkinson Congress was that genetics is transforming how researchers think about Parkinson's disease. Not because most people with Parkinson's have a genetic mutation—they don't—but because genetics is helping us understand the biological pathways that drive the disease itself.

In fact, some of the most exciting disease-modifying therapies currently being studied were developed because of discoveries made through genetic research.

The question is no longer simply:

"Is Parkinson's genetic?"

The more important question may be:

"What can genetics teach us about why Parkinson's develops in the first place?"

The Short Answer: Sometimes

Most people diagnosed with Parkinson's disease do not have a clearly identifiable inherited genetic mutation.

Researchers estimate that approximately 10–15% of Parkinson's cases have a known genetic component, while the majority are considered "idiopathic," meaning no single cause can be identified.

However, this distinction is becoming less clear.

Even when someone does not carry a known Parkinson's gene mutation, many of the biological pathways affected by genetic forms of Parkinson's appear to be disrupted in idiopathic Parkinson's disease as well.

This means genetic discoveries may ultimately help far more people than just those carrying specific mutations.

The Most Important Parkinson's Genes

Researchers have identified dozens of genes associated with Parkinson's disease risk, but a handful have emerged as particularly important because they appear to influence major biological pathways involved in disease progression.

The genes discussed most frequently throughout the conference included:

• LRRK2

• GBA1

• PINK1

• Parkin (PRKN)

Each tells us something different about how Parkinson's disease develops.

LRRK2: The Most Common Genetic Cause of Parkinson's Disease

Mutations in the LRRK2 gene represent the most common known genetic cause of Parkinson's disease.

Approximately 1–2% of all Parkinson's cases worldwide are linked to LRRK2 mutations, though rates are significantly higher in certain populations.

The LRRK2 protein plays important roles in cellular maintenance, lysosomal function, inflammation, and mitochondrial health.

At WPC, one researcher described abnormal LRRK2 activity as being:

"Like a bull in a china shop."

Instead of functioning normally, the mutated protein becomes overactive and may contribute to cellular damage over time.

Because of this, researchers have developed medications designed specifically to reduce LRRK2 activity.

Several major clinical trials are currently evaluating whether suppressing LRRK2 activity can slow disease progression.

While early results have been mixed, the field continues to view LRRK2 as one of the most promising precision medicine targets in Parkinson's disease.

GBA1: The Gene That Changed Everything

If there was one gene repeatedly mentioned throughout the conference, it was GBA1.

GBA1 mutations are among the most common genetic risk factors for Parkinson's disease.

Approximately 5–10% of people with Parkinson's disease carry a GBA1 variant.

The GBA1 gene produces an enzyme called glucocerebrosidase (often shortened to GCase).

This enzyme functions as part of the cell's waste-disposal and recycling system, known as the lysosome.

When GCase activity decreases, cells become less efficient at clearing damaged proteins and cellular debris.

This becomes particularly important because reduced GCase activity is associated with increased alpha-synuclein accumulation.

In other words, one of the major genetic pathways in Parkinson's disease appears directly connected to one of the major protein abnormalities discussed in the previous article.

Even more interesting, researchers now believe many people with idiopathic Parkinson's disease may also have reduced GCase activity despite not carrying a GBA1 mutation.

This is one reason GBA1 research has generated so much excitement.

Ambroxol: From Cough Medicine to Parkinson's Therapy

One of the most discussed GBA1 therapies at WPC was Ambroxol.

Originally developed as a cough medication, Ambroxol appears capable of increasing GCase activity and improving lysosomal function.

Researchers hope that by improving cellular waste disposal, Ambroxol may reduce alpha-synuclein accumulation and slow disease progression.

The ongoing ASPRO-PD Phase 3 trial is currently evaluating whether these biologic effects translate into meaningful clinical benefit.

The fact that a decades-old cough medication is now one of the most closely watched Parkinson's therapies highlights how rapidly the field is evolving.

PINK1 and Parkin: The Mitochondrial Connection

Two additional genes discussed frequently throughout the conference were PINK1 and Parkin.

These genes help regulate mitochondrial quality control.

Mitochondria are often described as the "power plants" of cells because they generate energy needed for cellular survival and function.

Dopamine-producing neurons have exceptionally high energy demands, making them particularly vulnerable to mitochondrial dysfunction.

Under normal circumstances, PINK1 and Parkin work together to identify damaged mitochondria and remove them before they can harm the cell.

When these systems fail, dysfunctional mitochondria accumulate, oxidative stress increases, and neurons become more vulnerable to degeneration.

One of the most important realizations emerging from modern Parkinson's research is that mitochondrial dysfunction appears to occur not only in people with PINK1 or Parkin mutations, but also in many individuals with idiopathic Parkinson's disease.

Again, a genetic discovery has helped uncover a broader biological process affecting many forms of Parkinson's disease.

Why Genetics Matters Even If You Don't Have a Mutation

One of the most important lessons from WPC was that Parkinson's genetics is no longer just about inheritance.

Genetics has become a roadmap for understanding disease biology.

Researchers are increasingly using genetic discoveries to identify:

• Biological pathways involved in disease progression

• New treatment targets

• Potential biomarkers

• Distinct Parkinson's subtypes

• Precision medicine opportunities

Even if you never undergo genetic testing—or test negative for known mutations—the discoveries coming from genetic research may still influence future treatment options.

The Rise of Precision Medicine

Historically, Parkinson's disease treatment has largely followed a one-size-fits-all model.

Regardless of why someone developed Parkinson's disease, treatment approaches have been relatively similar.

That is beginning to change.

Researchers increasingly believe that Parkinson's disease may consist of multiple biologically distinct subtypes.

Some individuals may have disease driven primarily by alpha-synuclein accumulation.

Others may have stronger lysosomal dysfunction.

Others may demonstrate more prominent mitochondrial abnormalities or inflammatory processes.

This has led to a growing emphasis on precision medicine.

The goal is to match the right treatment to the right patient based on the biological mechanisms driving their disease.

Where Are Genetic Therapies Headed?

Many of today's most promising disease-modifying therapy trials are directly tied to genetic discoveries.

Researchers are currently investigating:

• LRRK2 inhibitors

• GBA1-targeted therapies

• Lysosomal enhancers

• Mitochondrial therapies

• Gene therapies

• RNA-based therapies

• Precision medicine approaches guided by biomarkers and genetic testing

Some studies have produced encouraging results.

Others have failed to meet their primary endpoints.

But as several researchers emphasized throughout the conference, failed trials often teach us as much as successful ones.

The field continues to move forward rapidly.

The Bigger Picture

The most exciting thing about Parkinson's genetics may not be identifying who inherited a mutation.

It may be what those mutations are teaching us about the disease itself.

Genes such as LRRK2, GBA1, PINK1, and Parkin have opened windows into critical biological processes including protein clearance, mitochondrial health, inflammation, and cellular waste management.

These discoveries are helping researchers move beyond simply treating symptoms and toward therapies designed to address the underlying biology of Parkinson's disease.

And perhaps most importantly, they are helping reshape how we think about Parkinson's itself.

Rather than one disease with one cause and one treatment, Parkinson's increasingly appears to be a collection of overlapping biological pathways that may require different approaches for different people.

That shift—from symptom management toward biologically targeted precision medicine—may ultimately become one of the most important advances in Parkinson's research over the next decade.

Part 4: The New Way We Classify Parkinson's Disease

Why researchers are moving beyond symptom-based diagnosis toward biological staging systems, disease subtypes, and precision medicine.